Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...
Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...
The global sleep AIDS market size was valued at $59,815.10 million in 2020, and is projected to reach $111,920.10 million by 2030, registering a CAGR of 6.9%. David Correa Allied Market Research +1 ...
Moreover, the increased CO levels were normalized by treatment with CPAP in OSA patients. The present study indicated that increased serum CO levels are related to hypoxia during sleep in OSA ...
Fisher & Paykel Healthcare Corporation Limited has announced the application for quotation of 14,516 securities on the ASX under the code FPH. This initiative is part of an employee incentive scheme, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback